High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma
Authors:
- Ari KosunenAKAri Kosunen
- Kirsi RopponenKRKirsi Ropponen
- Jukka VirtaniemiJVJukka Virtaniemi
- Jari KellokoskiJKJari Kellokoski
- Eero KumpulainenEKEero Kumpulainen
- Risto PirinenRPRisto Pirinen
- Juhani NuutinenJNJuhani Nuutinen
- Risto JohanssonRJRisto Johansson
- Veli-Matti KosmaVKVeli-Matti Kosma
- 26 May 2006
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (3) , 267-272
Abstract
Background:Versican, an extracellular matrix proteoglycan, has been noted to be expressed in several malignant tumours and has been suggested to play an important role in cancer development and tumour growth.Aims:To investigate whether the versican expression level in the peritumoural stromal tissue of primary oral squamous cell carcinoma (OSCC) predicts relapse-free or disease-specific survival. Also, to study the associations between versican expression and several other clinicopathological variables, as well as tumour cell proliferation.Methods:Immunohistochemistry was used to study the expression of versican and tumour cell proliferative activity in 139 OSCCs. All pertinent clinical data were collected retrospectively from the hospital records.Results:In this cohort, versican expression did not correlate with the clinicopathological factors or tumour cell proliferation. In univariate analyses, higher risk for disease recurrence was associated with higher stromal versican expression score (p = 0.02), positive neck node status (p = 0.02), lower Karnofsky performance status (p = 0.03) and higher tumour cell proliferation index (p = 0.04). Increased disease-specific risk of death was associated with high stromal versican expression score (p = 0.005) higher T class (p = 0.002), positive neck node status (pConclusions:In this cohort, increased stromal versican expression correlated with both increased risk for disease recurrence and shortened survival. High stromal versican expression may thus be considered an independent and adverse prognostic marker in OSCC.Keywords
This publication has 39 references indexed in Scilit:
- Identification of genes and molecular pathways involved in the progression of premalignant oral epitheliaMolecular Cancer Therapeutics, 2005
- Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical studyJournal of Clinical Pathology, 2004
- The globular domains of PGM/versican modulate the proliferation‐apoptosis equilibrium and invasive capabilities of tumor cellsThe FASEB Journal, 2004
- Versican/PG‐M G3 domain promotes tumor growth and angiogenesisThe FASEB Journal, 2004
- Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy?Oral Oncology, 2004
- Versican in epithelial ovarian cancer: Relation to hyaluronan, clinicopathologic factors and prognosisInternational Journal of Cancer, 2003
- Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesotheliumThe Journal of Pathology, 2003
- Distribution of PG-M/Versican Variants in Human Tissues andde Novo Expression of Isoform V3 upon Endothelial Cell Activation, Migration, and Neoangiogenesis in VitroJournal of Biological Chemistry, 2002
- Binding of a Large Chondroitin Sulfate/Dermatan Sulfate Proteoglycan, Versican, to L-selectin, P-selectin, and CD44Journal of Biological Chemistry, 2000
- Cytokine regulation of proteoglycan production in fibroblasts: separate and synergistic effectsMatrix Biology, 1997